DOCSLIB.ORG

Pharmacokinetics Uses and Administration Adverse Effects And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacokinetics Uses and Administration Adverse Effects And Gadopentetic Acid/Gadoversetamide 1587 ble for those receiving medium- or low-risk agents, parti­ has paramagnetic properties and is used as a magnetic cularly patients aged 65 years or older. resonance contrast medium (p. 1580.1). It distributes Adverse Effects and Precautions M RA As for Gadopentetic Acid, p. 1586.2 and p. 1586.2, 1. Perazella A Rodby . Gadolinium-induced nephrogenic systemic mainly into extracellular fluid, but does not cross the blood­ fibrosis in patients with kidney disease. Am J Med 2007; 120: 561-2. brain barrier, and is used in imaging of cranial and spinal respectively. 2. Health Canada. Gadolinium-containing contrast agents and nephro­ structures and of the whole body, and in magnetic genic systemic fibrosis: update. Can Adverse React News 2007; 17 (4): 1-2. Reviews. Also available at: http://www.hc-sc.gc.ca/dhp-mps/alt_fonnats/hpfb­ resonance angiography. 1. Runge VM, Parker JR. Worldwide clinical safety assessment of dgpsa/pdf/medeff/carn-bceLvl7n4-eng.pdf (accessed 25/08110) Gadoteric acid is given intravenously as the meglumine gadoteridol injection: an update. Bur Radiol l997; 7 (suppl 5): 243-5. 3. Mareno-Romero JA, et al. Nephrogenic systemic fibrosis: a case series salt. It is available as a solution containing meglumine suggesting gadolinium as a possible aetiological factor. Br J Dermatol gadoterate 376.9mg/mL (0.5 mmol/mL). The usual dose in Hypersensitivity. For a report of an anaphylactoid reaction 2007; 157: 783-7. 4. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a adults and children is 0.2 mL/kg (0.1 mmol/kg) by with gadoteridol, see under Adverse Effects of Gadopente­ difference between gadolinium-based contrast agents? Semin Dial 200B; intravenous injection. A second dose of up to 0.4 mL/kg tic Acid, p. 1586.2. 21: 129-34. (0.2 mmol/kg) may be given within 30 minutes if necessary. 5. FDA. Gadolinium-containing contrast agents for magnetic resonance For angiography, a dose of 0.1 to 0.2 mL/kg (0.05 to imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and Pharmacokinetics MultiHance (issued 8th June 2006, updated 22nd December, 2006 and 0.1 mmol/kg) may be given, repeated if required. 23rd May, 2007). Available at: http://www.fda.gov/Drugs/DrugSafety/ Gadoteridol is distributed into extracellular fluid after PostmarketDrugSafetylnformationforPatientsandProviders/ intravenous injection. About 94% of a dose is excreted Administration in children. For doses of gadoteric add in ucml42884.htm (accessed 24/08/IO) unchanged in the urine within 24 hours. An elimination children, see Uses and Administration, above. 6. MHRA/CHM. Gadolinium-containing MRI contrast agents: nephrogenic half-life of about 1.57 hours has been reported. systemic fibrosis. Drug Safety Update 2007; 1 (I): 2-3. Available at: http:// www.mhra.gov.uk/home/idcplg?IdcService=GET_Fll.E&dDocName=­ CON203180l&RevisionSelectionMethod=LatestReleased (accessed Adverse Effects and Precautions r ti . .. 14/07/08) �r.�J?.?. �. ��� ................................ ............ ................ ............ 7. Health Canada. Association of nephrogenic systemic fibrosis/nephro­ As for Gadopentetic Add, p. 1586.2. Praprietary Preparations (details are given in Volume B) genic fibrosing dermopathy (NSF/NFD) with the use of gadolinium­ containing contrast agents (issued 9th March, 2007). Available at: Single-ingredient Preparations. Austral. : Prohance; Austria: Pro· http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/ Hypersensitivity. For reports of anaphylactoid reactions hance; Belg.: Prohance; Canad. : ProHance; Cz.: Prohance; gadolinium_nth-aah-eng.pdf (accessed 18/03/09) with gadoterate, see under Adverse Effects of Gadopentetic Denm.: Prohance; Fin.: Prohance; Fr.: Prohance; Ger. : Pro­ 8. Adverse Drug Reactions Advisory Committee (ADRAC). MRI scans with Acid, p. 1586.2. hance; Irl. : Probance; Ita!. : Prohance; Jp n: Prohance; Neth.: gadolinium-containing contrast agents and the risk of nephrogenic systemic fibrosis-caution in patients with renal impairment. Aust Prohance; Norw.: Prohance; Spain: Prohance; Swed.: Prohance; Adverse Drug Read Bull 2008; 17: 2. Also available at: http://www.tga. Switz. : Prohance; UK: Prohance; USA: Prohance. health.gov.au/adr/aadrb/aadr0802.pdf (accessed 18/03/09) Pharmacokinetics 9. MHRA/CHM. Gadolinium-containing contrast agents: new advice to Phannacopaeial Preparations minimise the risk of nephrogenic systemic fibrosis. Drug Safety Update Gadoterate is distributed into the extracellular space after USP 36: Gadoteridol Injection. 2010; 3 (6): 3-5. Available at: http:/lwww.mhra.gov.uk/Publications/ intravenous injection. It is not bound to plasma proteins. A Safetyguidance/DrugSafetyUpdate/CON068297 (accessed 22/03/10) plasma half-life of about 1.5 hours has been reported. It is not metabolised and about 90% of a dose is excreted in the Gadoversetamide (BAN. USAN, r!NNJ Pharmacokinetics urine within 24 hours. Gadopentetate is rapidly distributed into the extracellular space after intravenous injection. An elimination half-life of �.��J?.�.�<J.Ii��� .................................. ........................ ................. 1.6 hours has been reported. It is not metabolised and about Proprietary Preparations (details are given in Volume B) 90% of a dose is excreted in the urine within 24 hours. It does not appear to bind to plasma proteins. A small amount Single-ingredient Preparations. Arg. : Dotarem; Austral. : Dotar· is distributed into breast milk. Gadopentetate is removed by em; Austria: Artirem; Dotarem; Belg.: Artirem; Dotarem; Chile: haemodialysis. Dotarem; Cz. : Dotarem; Denm.: Dotarem; Fin.: Dotarem; Fr. : Artirem; Dotarem; Ger.: Artirem; Dotarem; Gr.: Dotarem; Hung.: Dotarem; Irl. : Dotarem; Israel: Dotarem; Ital. : Dotarem; �.��!?.�.��!����············································································ Neth.: Artirem; Dotarem; Norw. : Dotarem; NZ: Dotarem; Port.: Proprietary Preparations (details are given in Volume B) Dotarem; Rus.: Dotarem (,[{oTapeM); Spain: Dotarem; Swed.: Pharmacopoeias. In us. Dotarem; Switz. : Artirem; Dotarem; Thai. : Dotarem; Turk. : USP 36: Single-ingredient Preparations. Arg. : Magnevist; Opadte; View­ (Gadoversetamide). A white odourless powder. USA: Venez. : gam; Austral. : Magnevist; Austria: Magnegita; Magnevist; Dotarem; Dotarem; Dotarem. Freely soluble in water. Store.in airtight containers. Protect Belg.: Magnegita; Magnevist; Braz. : Magnevistan; Canad. : from light. Magnevist; Chile: Magnevistant; Cz. : Magnegita; Magnetolux; Magnevist; Denm.: Magnegitat; Magnevist; Magnograf; Fin.: Gadoteridol (BAN, USAN, riNNJ Uses and Administration Magnevist; Fr.: Magnegita; Magnevist; Ger.: Magnegita; Mag­ nevist; MR-Lux; Gr.: Magnevist; Hung.: Magnevist; India: Gadoversetamide is a nonionic gadolinium chelate with Magnevist; Irl. : Magnegita; Magnetolux; Magnevist; Israel: actions and uses similar to those of gadopentetic acid Gado-MRI; Magneto!; Ital. : Magnevist; Mex. : Viewgamt; Neth.: (p. 1586.1). It has paramagnetic properties and is used as a Magnegita; Magnevistt; Magnograft; Norw.: Magnevist; NZ: magnetic resonance contrast medium (p. 1580.1). It Magnevist; Philipp. : Gadomin; Port.: Ceacont; Magnegita; distributes mainly into extracellular fluid, but does not Magnevist; Rus.: Magnevist (Marnesucr); S.Afr. : Magnevist; cross the blood-brain barrier, and is used in imaging of Spain: Magnetolux; Magnevist; Magnograft; Swed.: Magnevist; cranial and spinal structures and of the whole body Switz.: Magnevist; Magnograf; MR-Lux; Turk.: Magnevist; UK: (particularly to visualise the liver). Magnevist; Ukr.: Magnilek (MarnUJieK); Tomovist (ToMOBHCT); Gadoversetamide is available as a solution containing USA: Magnevist; Venez. : Magnevistan. 330.9mg/mL (0.5 mmol/mL). The usual dose is 0.2 mL/kg Pharmacopoeial Preparations (0.1 mmol/kg) intravenously. USP 36: Gadopentetate Dimeglumine Injection. USP 36: (Gadoteridol). A white to off-white, odourless, crystalline powder. Freely soluble in water and in methyl Adverse Effects and Precautions alcohol; soluble in isopropyl alcohol. Store in airtight As for Gadopentetic Acid, p. 1586.2. containers. Protect from light. Interference with diagnostic tests. Like gadodiamide (see Uses and Administration p. 1585.3), gadoversetarnide may interfere with colori­ metric methods for measuring serum-calcium concentra­ Gadoteridol is a nonionic gadolinium chelate with actions tions. and uses similar to those of gadopentetic add (p. 1586.1). It Gadoversetamide may also interfere with measurement has paramagnetic properties and is used as a magnetic of serum-copper, iron, and zinc concentrations. resonance contrast medium (p. 1580.1). It distributes mainly into extracellular fluid, but does not cross the blood­ Renal impairment. For the view that gadoversetamide brain barrier, and is used in bnaging of cranial and spinal may carry an increased risk of the development of nephro­ structures and of the whole body. genic systemic fibrosis in patients with renal impainnent, Gadoteridol is available as a solution containing see p. 1586.3. 279.3 mg/mL (0.5 mmol/mL). The usual adult dose is 0.2 mL/kg (0.1 mmol/kg) intravenously; for CNS imaging, an additional dose of up to 0.4mL/kg (0.2 mmol/kg) may be Pharmacokinetics given up to 30 minutes after the first if necessary. A single Gadoversetamide is distributed into the extracellular space dose of 0.2 mL/kg (0.1 mmol/kg) is used in children from 6 after intravenous injection. It is not bound to plasma months of age (see also below).
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23
    1 26 May 2016 2 EMA/CHMP/337820/2016 3 Committee for Medicinal Products for Human Use (CHMP) 4 Guideline on core SmPC and Package Leaflet for gadoteric 5 acid 6 Draft Draft agreed by Radiopharmaceutical Drafting Group April 2016 Adopted by CHMP for release for consultation 26 May 2016 Start of public consultation 1 June 2016 End of consultation (deadline for comments) 30 September 2016 7 Comments should be provided using this template. The completed comments form should be sent to [email protected]. 8 Keywords Magnetic resonance, contrast media, gadolinium compounds, core SmPC, core Package Leaflet, gadoteric acid 9 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 10 Guideline on core SmPC and Package Leaflet for gadoteric 11 acid 12 Table of contents 13 Executive summary ..................................................................................... 3 14 1. Introduction (background) ...................................................................... 3 15 2. Scope....................................................................................................... 3 16 3. Legal basis .............................................................................................. 3 17 4. Core SmPC and Package Leaflet for gadoteric acid .................................
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
    [Show full text]